Skip to main content
. 2017 Dec 21;12(12):e0190125. doi: 10.1371/journal.pone.0190125

Fig 5. Ad5pK7 adenovirus can be “armed” with secreted forms of TR3-based cancer therapeutics.

Fig 5

(A) Adipose-derived MSCs from patient #15 were infected with Ad5pK7 carrying TR3eYFP and Meso64TR3eYFP genomes using an MOI of 5000. Representative images were taken and show expression of eYFP fluorescence (original magnification 10x). (B) In order to produce secreted TR3 drugs for functional activity testing, plateau-reaching MOIs were used for the respective virus preparation (MSC #20, MOI 2500). These were subsequently confirmed by flow cytometry to ensure that infection rates resulted in equivalent production of the respective biologics. (C) Cell killing profiles of TR3 and Meso64TR3 at increasing drug volumes were established on MUC16-deficient T cell leukemia cell line Jurkat. Supernatant of cells infected with Ad5-eYFP was used as a control. Please note that both drugs induced a dose-dependent cell death overlapping response curves, consistent with their known activity profiles. NS, not significant. (D) The same cell death determination as in (C) using identical drug volumes was performed in MUC16-positive OVCAR3 cells. Please note the much enhanced activity profile of the MUC16-targeted cancer drug Meso64TR3 relative to parental TR3. NS, not significant; *, P < 0.04.